Inhaled insulin delivery--where are we now?

Area of Science:

• Endocrinology
• Pharmacology
• Medical Technology

Background:

• The concept of inhaled insulin (INH) for diabetes treatment dates back to 1925.
• Technological advancements have overcome previous clinical challenges in INH development.
• Multiple INH systems are progressing through clinical trials, indicating significant progress.

Purpose of the Study:

• To evaluate the efficacy and safety of inhaled insulin (INH) therapy compared to subcutaneous (SC) insulin therapy for diabetes management.
• To assess patient preference and quality of life improvements with INH therapy.
• To investigate the long-term effects of INH on pulmonary function and immune responses.

Main Methods:

• Clinical trials comparing INH and SC insulin therapy in patients with type 1 and type 2 diabetes.
• Adverse event profiling and safety assessments.
• Patient-reported outcome measures focusing on lifestyle flexibility and injection avoidance.
• Ongoing long-term studies monitoring pulmonary function and immune markers.

Main Results:

• INH therapy demonstrates comparable glycaemic control to SC therapy without increased risk of hypoglycemia.
• Adverse events associated with INH are generally mild to moderate and similar to SC insulin.
• Patients overwhelmingly prefer INH therapy due to enhanced lifestyle flexibility and avoidance of injection pain.
• Small, reversible decreases in pulmonary diffusion capacity have been observed, but no clinically significant impact on pulmonary function or structure.

Conclusions:

• Inhaled insulin represents a viable and patient-preferred alternative to traditional subcutaneous insulin injections for diabetes management.
• While long-term safety studies are ongoing, current data suggest INH is safe and effective.
• INH therapy offers significant advantages in patient convenience and quality of life, marking a new era in diabetes care.